Marin, Ines
Serrano, Manuel http://orcid.org/0000-0001-7177-9312
Pietrocola, Federico http://orcid.org/0000-0002-2930-234X
Article History
Received: 2 January 2023
Accepted: 15 March 2023
First Online: 4 April 2023
Competing interests
: M.S. is shareholder of Senolytic Therapeutics, Life Biosciences, Rejuveron Senescence Therapeutics and Altos Labs, and is advisor of Rejuveron Senescence Therapeutics and Altos Labs. The funders had no role in the study design, data collection and analysis, decision to publish, or manuscript preparation. The remaining authors declare no competing interests.